Association between admission mean platelet volume and ST segment resolution after thrombolytic therapy for acute myocardial infarction.

Mean platelet volume (MPV), one of the indices of platelet reactivity has been shown to be related to impaired angiographic reperfusion in ST-segment elevation myocardial infarction (STEMI) patients treated with primary angioplasty or thrombolytics. However data regarding MPV and its association with ST-segment resolution; an indicator of epicardial and tissue level reperfusion in the setting of STEMI are limited. In this study, we aimed to investigate whether MPV on admission is associated with ST-segment resolution in STEMI patients treated with thrombolytics.
We retrospectively evaluated 232 consecutive patients with a diagnosis of first STEMI who were administered thrombolytic therapy within 12 hours of onset of chest pain. ST segment resolution based on baseline and 90 minute electrocardiographies were measured. Patients were grouped into two as with <50% and ≥50% ST-segment resolution. Admission MPV was measured and compared between two groups.
Admission MPV was higher in patients with <50% ST-segment resolution than patients with ≥50% ST-segment resolution (9.9±1.3 fL vs. 8.5±1.1 fL respectively, p<0.001). The receiver operating characteristic analysis yielded a cut-off value of 9.3 fL to predict ST-segment resolution, with sensivity and specifity being 66.7% and 77.9%, respectively. In-hospital mortality rate was high in patients with <50% ST -segment resolution (p=0.002).
High MPV on admission in STEMI patients treated with thrombolytics is associated with impaired ST segment resolution.
AuthorsÖzgür Kırbaş, Özge Kurmuş, Cemal Köseoğlu, Bilge Duran Karaduman, Ayşe Saatçi Yaşar, Recai Alemdar, Sina Ali, Mehmet Bilge
JournalAnadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology (Anadolu Kardiyol Derg) Vol. 14 Issue 8 Pg. 728-32 (Dec 2014) ISSN: 1308-0032 [Electronic] Turkey
PMID25188762 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: